Format

Send to

Choose Destination
Transfusion. 2016 Jan;56(1):195-202. doi: 10.1111/trf.13282. Epub 2015 Sep 10.

Establishing a reentry procedure for human immunodeficiency virus screening-reactive donors in China.

Author information

1
Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China.
2
Xinjiang Yili Blood Center, Yili, Xinjiaing, China.
3
Shanxi Changzhi Blood Center, Changzhi, Shanxi, China.
4
Liaoning Dalian Blood Center, Dalian, Liaoning, China.
5
Anhui Blood Center, Hefei, Anhui Province, China.
6
Fujian Blood Center, Fuzhou, Fujian Province, China.
7
Jiangsu Blood Center, Nanjing, Jiangsu, China.
8
Sichuan Nanchong Blood Center, Nanchong, Sichuan Province, China.
9
Hunan Hengyang Blood Center, Hengyang, Hunan, China.
10
Anhui Suzhou Blood Center, Suzhou, Anhui, China.
11
Sichuan Mianyang Blood Center, Mianyang, Sichuan Province, China.
12
Henan Kaifeng Blood Center, Kaifeng, Henan Province, China.
13
Sichuan Guangan Blood Center, Guangan, Sichuan, China.
14
Anhui Luan Blood Center, Luan, Anhui, China.
15
Guangdong Guangzhou Blood Center, Guangzhou, Guangdong, China.
16
Bloodworks Northwest (formerly Puget Sound Blood Center), Seattle, Washington.

Abstract

BACKGROUND:

Screening of blood donors for antibody to human immunodeficiency virus Types 1 and 2 (anti-HIV-1/2) and/or HIV nucleic acid test (NAT) is a well-established venue to prevent HIV transfusion-transmitted disease. However, with the current available technologies, HIV testing may result in donor loss due to false-positive results. This study intended to establish a donor reentry procedure for HIV screening-reactive donors in China.

STUDY DESIGN AND METHODS:

From September 1, 2013, to August 31, 2014, a total of 465 donors from 14 Chinese blood centers were enrolled in this study. Enrollment criteria include all donors who were screened reactive or belonged to the "gray zone" by enzyme-linked immunosorbent assay and/or reactive by NAT when tested at the local blood centers. All donor samples were sent to a central HIV confirmation laboratory where anti-HIV-1/2 and HIV individual-donation NATs were conducted. If the results were reactive for anti-HIV-1/2, then the samples were tested with a recombinant immunoblot assay.

RESULTS:

Based on the repeat testing at the central HIV confirmation laboratory 8 or 16 weeks after the study, 252 donors of 465 (54.2%) who completed the study could be classified in two categories for HIV status: 45 (18%) true positive and 207 (82%) false positive. A total of 213 of 465 (45.8%) donors were lost on follow-up and, thus, their HIV status cannot be determined with certainty. Based on these data, a donor reentry procedure was proposed.

CONCLUSION:

Based on our proposed donor reentry procedure for HIV screening-reactive donors, a majority of screening-positive donors (82%, 207/252) can be reentered safely.

PMID:
26360920
DOI:
10.1111/trf.13282
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center